SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii

Acinetobacter baumannii is responsible for 10% of all nosocomial infections and has >50% mortality rates when causing ventilator-associated pneumonia. In this proof-of-concept study, we evaluated SPR741, an antibiotic adjuvant that permeabilizes the Gram-negative membrane, in combination with rif...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Antimicrob Agents Chemother
Main Authors: Zurawski, Daniel V., Reinhart, Alexandria A., Alamneh, Yonas A., Pucci, Michael J., Si, Yuanzheng, Abu-Taleb, Rania, Shearer, Jonathan P., Demons, Samandra T., Tyner, Stuart D., Lister, Troy
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2017
Assuntos:
Experimental Therapeutics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5700309/
https://ncbi.nlm.nih.gov/pubmed/28947471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01239-17
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares